Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Benzinga · 3d ago
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.